

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/373,828

APPLICANT

Barbara K. Finck

FILING DATE

August 13, 1999

GROUP

~~1617~~ 1647

INFORMATION DISCLOSURE CITATION

NOV 26 1999

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>DR</i>	5,563,143	10/08/96	Cohan et al.	—	—	
	5,834,485	11/10/98	Dyke et al.	—	—	
	5,869,511	02/09/99	Cohan et al.	—	—	
<i>DR</i>	5,872,146	02/16/99	Baxter et al.	—	—	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>DR</i> WO 98/01555	01/15/98	PCT -	—	—	
<i>DR</i> WO 98/05357	02/12/98	PCT -	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DR</i>	Abu-Shakra, M., et al., "Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome," <i>J Rheumatol</i> 22:241-245, 1995
	Alonso, J.C., et al., "Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients," <i>Br J Rheumatol</i> 30:245-250, 1991
	Ameglio, F., et al., "Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy," <i>Dermatology</i> 189:359-363, 1994
	Arias, A, et al., "Tumor necrosis factor-alpha gene polymorphism in psoriasis," <i>Exp Clin Immunogenet</i> 14:118-122, 1997
	Austin, L., et al., "Intracellular TNF- α , IFN- γ , and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: single-cell analysis by flow cytometry," <i>J Dermatol Sci</i> 16 (Suppl. 1), March, 1998
	Austin, L., et al., "Intracellular TNF- α , IFN- γ , and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: single-cell analysis by flow cytometry," <i>J Invest Dermatol</i> 110:1 #4, April, 1998
	Bonifati, C., et al., "Correlated increases of tumour necrosis factor- α , interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity," <i>Clin Exp Dermatol</i> 19:383-387, 1994
	Bonifati, C., et al., "Soluble E-selectin and soluble tumour necrosis factor receptor (60kD) serum levels in patients with psoriasis," <i>Dermatology</i> 190:128-131, 1995
<i>DR</i>	Breathnach, S.M., "Spondyloarthropathies: psoriatic arthritis: etiology and pathogenesis," in <i>Rheumatology</i> , Mosby, London, John H. Klippel & Paul A. Dieppe, eds., 2d ed., 1998, pp. 22.1-22.4

DATE CONSIDERED

3/15/11

EXAMINER

David Lewis

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/308,828

RECEIVED

INFORMATION DISCLOSURE CITATION

APPLICANT

Barbara K. Finck

NOV 29 1999

FILING DATE

August 13, 1999

GROUP

TECH CENTER 1600/2900
1617

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

APR		Centola, G.M., et al., "Differential responses of human sperm to varying concentrations of pentoxifylline with demonstration of toxicity," <i>J Androl</i> 16(2):136-142, 1995 -
		Chodorowska, G., "Plasma concentrations of IFN- γ and TNF- α in psoriatic patients before and after local treatment with dithranol ointment," <i>J Eur Acad Dermatol Venereol</i> 10:147-151, 1998
		Clegg, D.O., et al., "Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis," <i>Arthritis Rheum</i> 39(12):2013-2020, 1996 -
		Cosman, D., "The tumor-necrosis-factor-related superfamily of ligands and receptors," in <i>Blood Cell Biochemistry Vol. 7: Hematopoietic Cell Growth Factors and Their Receptors</i> , Plenum Press, New York, A.D. Whetton & J. Gordon, eds., 1996, pp. 51-77
		Creaven, P.J. and Stoll, Jr., H.L., "Response to tumor necrosis factor in two cases of psoriasis," <i>J Am Acad Dermatol</i> 24:735-737, 1991
		Debets, R., et al., "Expression of cytokines and their receptors by psoriatic fibroblasts. II. Decreased TNF receptor expression," <i>Cytokine</i> 8(1):80-88, 1996
		Dobmeyer, J.M., et al., "Importance of HLA-DR+ and CD1a+ epidermal cells for cytokine production in psoriasis," <i>Adv Exp Med Biol</i> 378:539-541, 1995
		Dorwart, B.B., et al., "Chrysotherapy in psoriatic arthritis," <i>Arthritis Rheum</i> 21(5):513-515, 1978
		Dunky, A., et al., "Interactions of lymphocytes from patients with psoriatic arthritis or healthy controls and cultured endothelial cells," <i>Clin Immunol Immunopathol</i> 85(3):297-314, 1997
		Elferink, J.G.R., et al., "The effect of pentoxifylline on human neutrophil migration: a possible role for cyclic nucleotides," <i>Biochem Pharmacol</i> 54:475-480, 1997
		Ettehadi, P., et al., "Elevated tumour necrosis factor-alpha (TNF- α) biological activity in psoriatic skin lesions," <i>Clin Exp Immunol</i> 96:146-151, 1994
APR		Fukuoka, M., et al., "RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D ₃ (tacalcitol)," <i>Br J Dermatol</i> 138:63-70, 1998

DATE CONSIDERED

EXAMINER

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/373,828

INFORMATION DISCLOSURE CITATION

APPLICANT

Barbara K. Finck

FILING DATE

August 13, 1999

GROUP

1617

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

4/2		Gilhar, A., et al., "In vivo effects of cytokines on psoriatic skin grafted on nude mice: involvement of the tumour necrosis factor (TNF) receptor," <i>Clin Exp Immunol</i> 106:134-142, 1996
		Gladman, D.D., et al., "Longitudinal study of clinical and radiological progression in psoriatic arthritis," <i>J Rheumatol</i> 17:809-812, 1990
		Gladman, D.D., "Psoriatic arthritis: recent advances in pathogenesis and treatment," <i>Rheum Dis Clin North Am</i> 18(1):247-256, 1992
		Gladman, D.D., et al., "Psoriatic arthritis (PSA) - an analysis of 220 patients," <i>Quarterly Journal of Medicine, New Series</i> 62, 238:127-141, 1987
		Griffiths, C.E.M., et al., "Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in psoriasis," <i>Acta Derm Venereol (Stockh)</i> 76:2-5, 1996
		Helliwell, P.S. and Wright, V., "Spondyloarthropathies: psoriatic arthritis: clinical features," in <i>Rheumatology</i> , Mosby, London, John H. Klippel & Paul A. Dieppe, eds., 2d ed., 1998, pp. 21.1-21.8
		Höhler, T., et al., "A TNF- α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis," <i>J Invest Dermatol</i> 109:562-565, 1997
		Jones, G., et al., "Psoriatic arthritis: a quantitative overview of therapeutic options," <i>Br J Rheumatol</i> 36:95-99, 1997
		Kapp, A., et al., "Immunomodulating cytokines in atopic dermatitis and psoriasis: production of tumour necrosis factor and lymphotoxin by mononuclear cells <i>in vitro</i> ," <i>Br J Dermatol</i> 122:587-592, 1990
		Kristensen, M., et al., "Localization of tumour necrosis factor-alpha (TNF- α) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor," <i>Clin Exp Immunol</i> 94:354-362, 1993
		Löntz, W., et al., "Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 β and TNF- α ," <i>Free Radic Biol Med</i> 18(2):349-355, 1995
Rfa		Malkani, A.K., et al., "Normal response to tumor necrosis factor-alpha and transforming growth factor-beta by keratinocytes in psoriasis," <i>Exp Dermatol</i> 2:224-230, 1993

DATE CONSIDERED

3/15/1

EXAMINER

David Renu

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/373,828

APPLICANT

Barbara K. Finck

FILING DATE

August 13, 1999

GROUP

1617

INFORMATION DISCLOSURE CITATION

NOV 26 1999

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

QR		Markusheva, L.I., et al., "Serum tumor necrosis factor (alpha) in psoriasis," <i>Vefnik Dermatology</i> 0/3:8-11, 1997 ENGLISH ABSTRACT ONLY
		Mizutani, H., et al., "Role of increased production of monocytes TNF- α , IL-1 β and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments," <i>J Dermatol Sci</i> 14:145-153, 1997
		Mussi, A., et al., "Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis," <i>J Biol Regul Homeost Agents</i> 11:115-118, 1997
		Nickoloff, B.J., et al., "Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis," <i>Am J Pathol</i> 138(1):129-140, 1991
		Nickoloff, B.J., "The cytokine network in psoriasis," <i>Acta Dermatol</i> 127:871-884, 1991
		Okubo, Y. and Koga, M., "Peripheral blood monocytes in psoriatic patients overproduce cytokines," <i>J Dermatol Sci</i> 17:223-232, 1998
		Omulecki, A., et al., "Is pentoxifylline effective in the treatment of psoriasis?" <i>J Am Acad Dermatol</i> 34(4):714-715, 1996
		Oxholm, A., "Epidermal expression of interleukin-6 and tumour necrosis factor-alpha in normal and immunoinflammatory skin states in humans," <i>APMIS</i> 100 (Suppl. 24):5-32, 1992
		Partsch, G., et al., "Highly increased levels of tumor necrosis factor- α and other proinflammatory cytokines in psoriatic arthritis synovial fluid," <i>J Rheumatol</i> 24:518-523, 1997
		Partsch, G., et al., "T cell derived cytokines in psoriatic arthritis synovial fluids," <i>Ann Rheum Dis</i> 57:691-693, 1998
		Partsch, G., et al., "Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid," <i>J Rheumatol</i> 25:105-110, 1998
QR		Pigatto, P.D., et al., "Factors secreted by untreated psoriatic monocytes enhance neutrophil functions," <i>J Invest Dermatol</i> 94:372-376, 1990

DATE CONSIDERED

3/15/11

EXAMINER

David Lence

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/373,828

INFORMATION DISCLOSURE CITATION

APPLICANT

Barbara K. Finck

FILING DATE

August 13, 1999

GROUP

1617

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

QR		Reichrath, J., et al., "Topical calcitriol (1,25-Dihydroxyvitamin D ₃) treatment of psoriasis: an immunohistological evaluation," <i>Acta Derm Venereol (Stockh)</i> 77:268-272, 1997
		Ritchlin, C., et al., "Patterns of cytokine production in psoriatic synovium," <i>J Rheumatol</i> 25:1544-1552, 1998
		Sagawa, Y., et al., "Is sustained production of tumor necrosis factor- α relevant to the development of pustular psoriasis?" <i>Dermatology</i> 187:81-83, 1993
		Salvarani, C., et al., "Psoriatic arthritis," <i>Curr Opin Rheumatol</i> 10:299-305, 1998
		Seishima, M., et al., "Increased serum soluble Fas, tumor necrosis factor α and interleukin 6 concentrations in generalized pustular psoriasis," <i>Dermatology</i> 196:371-372, 1998
		Shiohara, T., et al., "Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis," <i>J Am Acad Dermatol</i> 27:568-574, 1992
		Takematsu, H., et al., "Systemic TNF administration in psoriatic patients: a promising therapeutic modality for severe psoriasis," <i>Br J Dermatol</i> 124:209-210, 1991
		Terajima, S., et al., "An important role of tumor necrosis factor- α in the induction of adhesion molecules in psoriasis," <i>Arch Dermatol Res</i> 290:246-252, 1998
		Tigalnova, M., et al., "Serum levels of interferons and TNF- α are not correlated to psoriasis activity and therapy," <i>Acta Derm Venereol (Stockh) Suppl.</i> 186:25-27, 1994
		Veale, D., et al., "Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis," <i>Arthritis Rheum</i> 36(7):893-900, 1993
		Willkens, R.F., et al., "Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis," <i>Arthritis Rheum</i> 27(4):376-381, 1984
QR		Weinblatt, M.E., et al., "A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate," <i>N Engl J Med</i> 340:253-259, 1999

DATE CONSIDERED

3/15/11

EXAMINER

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945 JAN 24 2001

SERIAL NO.

09/373,828

INFORMATION DISCLOSURE CITATION

APPLICANT

Barbara K. Fink

FILING DATE

August 13, 1999

GROUP

164

(Use several sheets if necessary)

EXAMINER

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

deRie, M.A. et al., "Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation," *Dermatology* 196:412-417, 1998

Mease, P.J. et al., "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial," *Lancet* 356:385-390, 2000

Mease, P. et al., "(ETANERCEPT) in patients with psoriatic arthritis and psoriasis," Presented at American College of Rheumatology, Nov. 13-19, 1999, Boston, MA, Vol. 42(9 Supp) Sept. 1999, Abstract No 1835

Nickoloff, B.J., "Pathogenesis and immunointervention strategies for psoriasis," *Mol Med Today*, 512-513, 1998

Yazici, Y. et al., "Etanercept in the treatment of severe, resistant psoriatic arthritis," *Arthritis Rheum* 42(Suppl.):S379, 9 SEP 1999

DATE CONSIDERED

EXAMINER

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/3/3,828

INFORMATION DISCLOSURE CITATION

APPLICANT

Barbara K. Finck

FILING DATE

August 13, 1999

(Use several sheets if necessary)

GROUP

JAN 24 2001

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JP</i>	4,965,271	10/23/90	Mandrell et al.			
	5,096,906	03/17/92	Mandrell et al.			
	5,196,430	03/23/93	Mandrell et al.			
	5,420,154	05/30/95	Christensen et al.			
	5,508,300	05/16/96	Duplantier			
	5,541,219	07/30/96	Fenton et al.			
	5,596,013	01/21/97	Duplantier			
	5,629,285	05/13/97	Black et al.			
	5,691,382	11/25/97	Crimmin et al.			
	5,700,838	12/23/97	Dickens et al.			
	5,747,514	05/05/98	Beckett et al.			
	5,756,449	05/26/98	Andersen et al.			
	5,795,859	08/18/98	Rathjen et al.			
	5,821,262	10/13/98	Crimmin et al.			
	5,888,511	03/30/99	Skurkovich et al.			
	5,958,413	09/28/99	Anagnostopoulos et al.			
<i>JP</i>	6,020,323	02/01/00	Cohen et al.			

DATE CONSIDERED

EXAMINER

David Rana

3/15/11

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2945

SERIAL NO.

09/372828

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Barbara K. Finck

FILING DATE

August 13, 1999

GROUP

16801

RECEIVED
FEB 02 2001
TECH CENTER 1600/2300

FOREIGN PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
[Signature]	WO 95/06031	03/02/95	PCT	[Signature]	[Signature]		
	WO 95/35283 ✓	12/28/95	PCT				
	WO 95/35285 ✓	12/28/95	PCT				
	WO 96/00215 ✓	01/04/96	PCT				
	WO 96/01825 ✓	01/25/96	PCT				
	WO 98/17799 ✓	04/30/98	PCT				
	WO 98/24463 ✓	08/11/98	PCT				
	WO 98/46642 ✓	10/22/98	PCT				
	WO 99/15524 ✓	04/01/99	PCT				
	WO 99/18095 ✓	04/15/99	PCT				
	WO 99/31128 ✓	06/24/99	PCT				
	GB2291422A ✓	01/24/96	EP				
	EP 516785B1 ✓	12/09/92	EP				
	EP 626 389A1 ✓	11/30/94	EP				
	EP 639 079B1 ✓	11/11/93	EP				
[Signature]	EP 869 179 A1 ✓	10/07/98	EP				
	EP 927 758A2	07/07/99	EP				

DATE CONSIDERED

3/15/11

EXAMINER

[Signature]

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.